Increasing Complexity of Oncology Trials
With an estimated 1.9 million cancer diagnoses and more than 600,000 cancer deaths forecasted in the US alone in 2021, it is more important than ever to continue the ongoing push for new, effective cancer treatments. Fortunately, there are more oncology trials in clinical development than ever before. In fact, the number of oncology trials has nearly doubled in the past 10 years. But the complexity of oncology trials has grown as well, making them more challenging to recruit and execute and more difficult to retain patients.
With competition and complexity at an all time high, you need a CRO that understands the unique challenges of oncology trials and the expertise to operationalize your study design successfully. Whether you’re embarking on your Phase I dose-finding study or gearing up for your Pivotal Phase III trial, Aperio will provide the expertise and attention your trial deserves.
Our Experience
Aperio team members have managed and executed more than 140 oncology trials across multiple indications, treatment modalities and phases.
142
Oncology
Studies
80%
Staff with
Oncology Experience
32
Oncology
Indications
We have extensive clinical development expertise in a variety of study designs and specialties, such as:
- Dose escalation studies
- Early to late phase trials
- Operationalizing complex, challenging protocols
- Cohort management, umbrella, basket studies, adaptive trials
- Site feasibility
- Patient recruitment / retention
- Oncology Focused EDC Programming
- Data driven approach / analytics
- Immuno-Oncology
- Oncolytic virus experience
Our team members are experienced across a wide-range of solid tumor and hematology-oncology indications, including lung, breast, prostate and gynecological cancers, non-Hodgkin’s lymphoma, skin and hematological cancers.
SOLID TUMOR
INDICATIONS
- Advanced Solid Tumors
- Lung
- Breast
- Gastrointestinal
- Prostate
- Non-Small Cell Lung
- Skin
- Pancreatic
- Colorectal
- Bladder
- Head and Neck
- Renal
- Gynecologic Cancer
- Glioblastoma
- Glioma
- Thyroid
HEMATOLOGY ONCOLOGY
INDICATIONS
- Chronic Lymphocytic Leukemia (CLL)
- Hematologic Malignancies
- Acute Myeloid Leukemia (AML)
- Leukemia
- Non-Hodgkin’s Lymphoma
- Lymphoma
- Acute Lymphocytic Leukemia (ALL)
- Bone Marrow
- Myelodysplastic Syndrome (MDS)
It has been a pleasure working with this team. I wanted to compliment the entire team on their professionalism. It is a pleasure working with a group of seasoned professionals that understand what is needed to get the job done. I especially wanted to compliment the Aperio Project Manager for her calm demeanor, dedication, and leadership in doing all that it takes to move the project forward. Congratulations on putting together such a great team and thanks to the entire team for their ongoing tireless support.
Very pleased with the transparency, level of communication and spot on execution of deliverables. Aperio rocks in comparison to other CROs!
MEET THE EXPERT
Need help from an oncology expert?
Aperio’s Chief Operating Officer Suzanne Kincaid has 25+ years’ experience managing phase I-III oncology trials. She has deep expertise in operationalizing a wide range of complex oncology trial designs. Suzanne was the Study Delivery Program Leader of AstraZeneca’s Oncology Phase I Team for the US and Director of Operations at Sarah Cannon’s Phase I Drug Development Unit.
Reach out to Suzanne with questions about your oncology trial needs today.
